Haller Daniel G
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, PA, USA.
Semin Oncol. 2004 Dec;31(6 Suppl 14):10-6. doi: 10.1053/j.seminoncol.2004.11.006.
Since the late 1970s, clinical researchers have investigated the use of platinum compounds administered as single agents or in combination with other drugs for the treatment of a variety of cancers, including gastrointestinal cancers. After extensive clinical development, oxaliplatin has become an important option in the treatment of colorectal cancer, and its role in the treatment of other gastrointestinal cancers (and other cancers) remains a focus of intense investigation. Historically, platinum compounds have shown limited single-agent activity in pancreatic cancer, although more recent studies have explored potential synergies using platinum-based combinations. In addition, platinum agents have long been used in the treatment of advanced gastroesophageal tumors (typically 5-fluorouracil and cisplatin combinations), although poor outcomes in this disease clearly indicate a need for the development of more active agents. This review will examine recent clinical data on the use of platinum-based chemotherapies for the treatment of these gastrointestinal cancers.
自20世纪70年代末以来，临床研究人员一直在研究铂类化合物作为单一药物或与其他药物联合使用治疗包括胃肠道癌症在内的多种癌症的情况。经过广泛的临床开发，奥沙利铂已成为治疗结直肠癌的重要选择，其在治疗其他胃肠道癌症（以及其他癌症）中的作用仍是深入研究的重点。从历史上看，铂类化合物在胰腺癌中的单药活性有限，尽管最近的研究探索了基于铂类的联合用药的潜在协同作用。此外，铂类药物长期以来一直用于治疗晚期胃食管肿瘤（通常是5-氟尿嘧啶和顺铂联合使用），尽管该疾病的治疗效果不佳清楚地表明需要开发更有效的药物。本综述将研究近期关于铂类化疗用于治疗这些胃肠道癌症的临床数据。
